Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Sipavibart in Healthy Japanese Adults
NCT05932641Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sipavibart in coronavirus disease 2019 (COVID-19) (6 cohorts), sponsored by AstraZeneca. Primary endpoints: Adverse Events at Day 91, Serious Adverse Events at Day 361 and 9 more. Started Jul 2023; status: completed.
02
Drugs
sipavibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05932641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932641.